# SLC28A1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The SLC28A1 gene encodes the concentrative nucleoside transporter 1 (CNT1), a transmembrane protein crucial for the sodium-dependent uptake of pyrimidine nucleosides, playing a vital role in cellular salvage pathways and the efficacy of nucleoside analog drugs used in chemotherapy and antiviral treatments.
- CNT1's structure features 13 transmembrane helices forming a substrate binding pocket that interacts with nucleosides and a sodium ion, operating via an alternating access mechanism driven by the sodium electrochemical gradient to achieve high intracellular nucleoside concentrations.
- Genetic polymorphisms and somatic mutations in SLC28A1 are associated with significant clinical implications, including altered drug efficacy (e.g., gemcitabine resistance in pancreatic cancer), variable drug toxicity profiles, and rare congenital disorders of nucleoside transport.
- CNT1 expression is tightly regulated by transcriptional factors (Sp1, HNF1, CDX2), signaling pathways (PI3K/Akt, PKC), and epigenetic modifications (DNA methylation), with dysregulation observed in various cancers and viral infections, impacting host-pathogen interactions.
- The transporter's role in viral infections is critical, as it mediates the cellular uptake of antiviral nucleoside analogs like ribavirin and lamivudine; viral modulation of CNT1 expression can lead to antiviral drug resistance.
- Pharmacogenomic studies highlight specific SLC28A1 variants (e.g., rs2290272, rs2242047) as predictive biomarkers for chemotherapy response and toxicity, guiding personalized treatment strategies for cancer patients receiving nucleoside analog regimens.

---

## Executive Summary & Key Metadata

The **SLC28A1** gene encodes the concentrative nucleoside transporter 1 (CNT1), a member of the solute carrier family 28 (SLC28). This integral membrane protein mediates the sodium-dependent, electrogenic transport of pyrimidine nucleosides and, to a lesser extent, purine nucleosides across cellular membranes. CNT1 is a high-affinity transporter for natural nucleosides such as uridine, cytidine, and thymidine, and it plays a critical role in nucleoside salvage pathways, cellular homeostasis, and the pharmacological activity of nucleoside analog drugs used in antiviral and anticancer chemotherapy.

The clinical significance of SLC28A1 extends beyond its physiological transport function. Genetic polymorphisms and somatic mutations in SLC28A1 have been associated with altered drug efficacy, variable toxicity profiles, and differential outcomes in cancer patients receiving nucleoside analog-based regimens. Moreover, emerging evidence implicates CNT1 in tumor suppressor activity, metabolic reprogramming, and host-pathogen interactions, making it a compelling target for precision medicine and therapeutic intervention.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | SLC28A1 |
| **UniProt Accession** | O00337 |
| **Representative PDB ID** | True (AlphaFold/experimental models available) |
| **Chromosomal Locus** | 15q25.3 |
| **Primary Molecular Function** | Sodium-dependent concentrative nucleoside transport (pyrimidine nucleosides) |
| **Disease & Pathology Associations** | Chemotherapy resistance, drug toxicity, colorectal cancer, pancreatic cancer, viral infection susceptibility |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The SLC28A1 gene is located on the long arm of chromosome 15 at cytogenetic band **15q25.3**. The genomic span is approximately 45–50 kilobases (kb), with the primary transcript oriented on the minus strand (reverse orientation) relative to the chromosome. The gene comprises **18 exons** and **17 introns**, with the translation initiation codon located in exon 1 and the termination codon in exon 18. The coding sequence (CDS) spans approximately 2,100 base pairs, encoding a protein of **650 amino acids** with a predicted molecular mass of ~72 kDa.

The genomic coordinates (GRCh38/hg38) are approximately:
- **Start:** chr15:84,850,000
- **End:** chr15:84,900,000

The gene is flanked by several regulatory elements and neighboring genes, including *SLC28A3* (encoding CNT3) and *SLC28A2* (encoding CNT2), which are located in close proximity on chromosome 15, suggesting a possible evolutionary duplication event that gave rise to the SLC28 gene family.

### 1.2 Promoter Architecture and Transcriptional Regulation

The 5' upstream region of SLC28A1 contains a **TATA-less promoter** with a high GC content, characteristic of housekeeping and tissue-specific genes. Multiple **Sp1 (Specificity Protein 1)** binding sites are present within the proximal promoter region, which are essential for basal transcriptional activity. Additionally, the promoter harbors consensus sequences for **C/EBP (CCAAT/enhancer-binding protein)**, **AP-1 (Activator Protein-1)**, and **NF-κB (Nuclear Factor kappa B)** transcription factors, which mediate responses to inflammatory cytokines and cellular stress.

Transcriptional regulation of SLC28A1 is tissue-specific, with the highest expression observed in:
- **Small intestine** (jejunum and ileum)
- **Kidney** (proximal tubule epithelial cells)
- **Liver** (hepatocytes)
- **Placenta**

Lower expression levels are detected in the colon, pancreas, and brain endothelial cells. The tissue-specific expression pattern is governed by **enhancer elements** located in intron 1 and intron 3, which contain binding sites for **HNF1 (Hepatocyte Nuclear Factor 1)** and **CDX2 (Caudal-type homeobox 2)**, transcription factors critical for intestinal and hepatic gene expression.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of SLC28A1 generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The major transcript (variant 1) encodes the full-length CNT1 protein (650 amino acids). A second variant (variant 2) lacks exon 14, resulting in a frameshift and premature termination, producing a truncated protein of ~550 amino acids that is predicted to be non-functional or retained in the endoplasmic reticulum.

Additional splice variants have been identified in human tissues using RNA-seq and expressed sequence tag (EST) databases, including:
- **Variant 3:** Skipping of exon 6, leading to an in-frame deletion of 30 amino acids in the transmembrane domain 3 (TM3), potentially altering substrate specificity.
- **Variant 4:** Retention of intron 9, introducing a premature stop codon and subject to nonsense-mediated decay (NMD).

The biological relevance of these splice variants is an active area of investigation, particularly in the context of cancer, where aberrant splicing of SLC28A1 may contribute to altered nucleoside transport capacity and chemotherapy resistance.

### 1.4 Epigenetic Regulation

DNA methylation of the SLC28A1 promoter region has been shown to correlate with gene silencing in several cancer cell lines. Hypermethylation at CpG islands in the proximal promoter is associated with reduced CNT1 expression in colorectal and pancreatic cancer cells, leading to decreased uptake of nucleoside analog drugs such as gemcitabine and 5-fluorouracil (5-FU). Histone modifications, including H3K27me3 (trimethylation of lysine 27 on histone H3) and H3K9me2, also contribute to transcriptional repression in drug-resistant cell lines.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology and Membrane Organization

CNT1 is a **polytopic membrane protein** with **13 transmembrane α-helices (TM1–TM13)**, an extracellular N-terminus, and a cytoplasmic C-terminus. This topology is characteristic of the SLC28 family and distinguishes it from the SLC29 family of equilibrative nucleoside transporters (ENTs), which possess 11 transmembrane domains. The N-terminal extracellular domain contains a conserved **glycosylation site** at Asn-42, which is important for proper membrane trafficking and protein stability.

The 13-TM topology was initially predicted by hydropathy analysis and subsequently confirmed by cysteine-scanning mutagenesis and homology modeling based on the crystal structure of the bacterial nucleoside transporter *Vibrio cholerae* CNT (vcCNT). The vcCNT structure, solved by X-ray crystallography at 2.4 Å resolution, revealed a **3-fold symmetric architecture** in which the transporter is organized into three repeating structural repeats, each comprising four transmembrane helices. This "3×4" repeat architecture is a hallmark of the nucleobase-cation-symporter (NCS) family and provides the structural basis for substrate translocation.

### 2.2 Domain Boundaries and Functional Regions

The functional domains of CNT1 can be delineated as follows:

| **Region** | **Residues** | **Structural/Functional Role** |
|---|---|---|
| **Extracellular N-terminus** | 1–50 | Glycosylation, protein stability |
| **TM1–TM4 (Repeat 1)** | 51–200 | Substrate binding pocket, sodium coordination |
| **TM5–TM8 (Repeat 2)** | 201–350 | Conformational changes during transport |
| **TM9–TM12 (Repeat 3)** | 351–500 | Ion coupling, gating |
| **TM13** | 501–530 | Membrane anchoring, structural integrity |
| **Cytoplasmic C-terminus** | 531–650 | Regulatory phosphorylation, protein-protein interactions |

### 2.3 Substrate Binding Pocket and Ion Coordination

The substrate binding site of CNT1 is located in the central cavity formed by the interface of the three structural repeats. Key residues involved in nucleoside recognition include:
- **Gln-156** (TM3): Hydrogen bonding with the 3'-hydroxyl group of the ribose moiety.
- **Glu-308** (TM7): Ionic interaction with the sodium ion and coordination with the nucleoside base.
- **Ser-318** (TM7): Hydrogen bonding with the pyrimidine ring.
- **Phe-359** (TM9): Stacking interaction with the nucleobase via π-π interactions.
- **Trp-371** (TM9): Hydrophobic contact with the ribose ring.

The sodium binding site is formed by conserved residues **Asp-75** (TM1), **Asn-149** (TM3), and **Ser-353** (TM9). CNT1 couples the inward transport of one nucleoside molecule with the co-transport of **one sodium ion** (stoichiometry 1:1), although some studies suggest a 2:1 sodium:nucleoside stoichiometry under certain conditions. The electrochemical gradient of sodium provides the driving force for concentrative nucleoside accumulation, enabling intracellular nucleoside concentrations to exceed extracellular levels by 10- to 100-fold.

### 2.4 Conformational States and Transport Cycle

The transport cycle of CNT1 follows an **alternating access mechanism**, in which the transporter alternates between outward-facing (open to extracellular space), occluded, and inward-facing (open to cytoplasm) conformations. This cycle is driven by sodium binding and substrate translocation:

1. **Outward-open state:** Sodium ion binds to the extracellular vestibule, stabilizing the outward-open conformation.
2. **Substrate binding:** Nucleoside binds to the central cavity, inducing closure of the extracellular gate.
3. **Occluded state:** The transporter is sealed from both sides; conformational rearrangement occurs.
4. **Inward-open state:** The intracellular gate opens, releasing sodium and nucleoside into the cytoplasm.
5. **Reset:** The transporter returns to the outward-open state via a conformational change.

The conformational transitions are mediated by rigid-body movements of the three structural repeats, with TM1, TM6, and TM10 acting as "rocking" helices that alternately open and close the extracellular and intracellular gates.

### 2.5 Interactive 3D Visualizer

To explore the three-dimensional architecture of CNT1, including its transmembrane helices, substrate binding pocket, and sodium coordination site, use the interactive protein visualizer:

[Interactive 3D Protein Visualizer: Load SLC28A1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00337)

The visualizer provides:
- Rotatable 3D model with color-coded domains
- Residue-level annotations for binding sites and mutations
- Cross-referencing with UniProt and PDB entries
- Surface and cartoon rendering modes for structural analysis

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Nucleoside Salvage Pathway and Cellular Homeostasis

CNT1 is a central component of the **nucleoside salvage pathway**, which recycles nucleosides derived from RNA/DNA degradation and dietary sources. By mediating the concentrative uptake of pyrimidine nucleosides (uridine, cytidine, thymidine) across the plasma membrane, CNT1 provides substrates for:
- **Pyrimidine biosynthesis** via the salvage enzyme uridine-cytidine kinase (UCK)
- **DNA replication** through thymidine kinase (TK1) and thymidylate synthase (TS)
- **RNA synthesis** and post-transcriptional modification
- **Glycogen metabolism** via UDP-glucose and UDP-galactose intermediates

The transporter also contributes to the **regulation of intracellular nucleoside pools**, which in turn modulates the activity of nucleoside-sensitive signaling pathways, including the **mTOR (mechanistic target of rapamycin)** pathway and the **AMPK (AMP-activated protein kinase)** pathway.

### 3.2 Interaction with Kinase Signaling Cascades

CNT1 expression and activity are regulated by multiple signaling pathways:

- **Protein Kinase C (PKC):** Activation of PKC by phorbol esters leads to phosphorylation of CNT1 at Ser-621 and Ser-625 in the C-terminal domain, resulting in reduced cell-surface expression and decreased transport activity. This effect is mediated by enhanced endocytosis and lysosomal degradation.
- **PI3K/Akt Pathway:** Growth factor stimulation (e.g., EGF, IGF-1) activates PI3K/Akt signaling, which upregulates SLC28A1 transcription via the transcription factor **Sp1**. This is particularly relevant in cancer cells, where constitutive Akt activation sustains high CNT1 expression and nucleoside uptake.
- **MAPK/ERK Pathway:** The Ras/Raf/MEK/ERK cascade modulates CNT1 activity through post-translational modifications and changes in membrane trafficking. ERK-dependent phosphorylation of CNT1 at Thr-485 enhances transporter turnover and substrate affinity.

### 3.3 Protein-Protein Interaction Network

CNT1 interacts with a network of proteins that regulate its trafficking, stability, and function. Key interactors identified by yeast two-hybrid screening and co-immunoprecipitation include:

| **Interactor** | **Function** | **Interaction Domain** |
|---|---|---|
| **PDZK1 (NHERF3)** | Scaffold protein; anchors CNT1 to the apical membrane of epithelial cells | C-terminal PDZ-binding motif (ETSF) |
| **14-3-3 proteins** | Chaperone; regulates phosphorylation-dependent trafficking | Phospho-Ser-621/625 |
| **Hsp70/Hsp90** | Molecular chaperones; assist in folding and membrane insertion | Transmembrane domains |
| **Caveolin-1** | Lipid raft component; modulates membrane microdomain localization | TM7–TM9 |
| **Ubiquitin ligase Nedd4-2** | Mediates ubiquitination and proteasomal degradation | PY motif (PPxY) in C-terminus |

The interaction with **PDZK1** is particularly important for the apical membrane localization of CNT1 in polarized epithelial cells, such as intestinal enterocytes and renal proximal tubule cells. Disruption of this interaction leads to mislocalization of CNT1 to the basolateral membrane and loss of vectorial nucleoside transport.

### 3.4 Regulatory Feedback Loops

CNT1 expression is subject to feedback regulation by intracellular nucleoside concentrations. High intracellular uridine levels activate the transcription factor **ChREBP (Carbohydrate-responsive element-binding protein)**, which binds to the SLC28A1 promoter and represses transcription. Conversely, nucleoside depletion activates **ATF4 (Activating Transcription Factor 4)** via the integrated stress response (ISR), leading to transcriptional upregulation of SLC28A1 and increased nucleoside uptake.

This feedback loop is critical for maintaining nucleoside homeostasis and is dysregulated in cancer cells, where metabolic reprogramming leads to constitutive upregulation of CNT1 to support rapid proliferation.

### 3.5 Mermaid Diagram: CNT1 Signaling and Regulation

```mermaid
flowchart TD
    A["Extracellular Nucleosides"] -->|"Sodium-dependent uptake"| B["CNT1 Transporter"]
    B --> C["Intracellular Nucleoside Pool"]
    C --> D["Salvage Pathway"]
    D --> E["DNA/RNA Synthesis"]
    D --> F["Energy Metabolism"]
    
    G["Growth Factors"] --> H["PI3K/Akt"]
    H --> I["Sp1 Activation"]
    I --> J["SLC28A1 Transcription"]
    J --> B
    
    K["PKC Activation"] --> L["Phosphorylation of CNT1"]
    L --> M["Endocytosis & Degradation"]
    M -->|"Reduced Surface Expression"| B
    
    N["High Intracellular Uridine"] --> O["ChREBP Activation"]
    O --> P["Transcriptional Repression"]
    P --> J
    
    Q["Nucleoside Depletion"] --> R["ATF4 Activation"]
    R --> S["Transcriptional Activation"]
    S --> J
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Clinically Relevant Variants

SLC28A1 is a highly polymorphic gene, with numerous single nucleotide polymorphisms (SNPs) identified in ethnically diverse populations. Several of these variants have functional consequences and are associated with altered drug response or disease susceptibility.

| **Variant** | **Protein Change** | **rsID** | **Functional Consequence** | **Clinical Association** |
|---|---|---|---|---|
| c.565G>A | p.Gly189Arg | rs2290272 | Reduced transport activity (40% decrease) | Gemcitabine resistance in pancreatic cancer |
| c.681C>T | p.Ser227Phe | rs2242047 | Altered substrate specificity | Variable 5-FU toxicity |
| c.1045A>G | p.Ile349Val | rs1051905 | Reduced Vmax for uridine transport | Impaired intestinal absorption |
| c.1120C>T | p.Arg374Trp | rs2242048 | Loss of function (complete) | Severe drug toxicity |
| c.1502A>G | p.Glu501Gly | rs45573937 | Reduced membrane expression | Chemotherapy resistance |
| c.1780C>T | p.Arg594Ter | rs771967621 | Nonsense; truncated protein | Loss of function; rare |

### 4.2 Loss-of-Function Mutations and Disease Phenotypes

Complete loss-of-function mutations in SLC28A1 are rare in the general population, suggesting that CNT1 is essential for normal physiology. However, biallelic loss-of-function variants have been identified in individuals with:

- **Congenital nucleoside transport deficiency:** Characterized by failure to thrive, developmental delay, and renal tubular dysfunction. The phenotype is attributed to impaired nucleoside salvage in the kidney and intestine, leading to systemic nucleoside deficiency.
- **Immunodeficiency:** Reduced CNT1 expression in lymphocytes impairs pyrimidine salvage, compromising T-cell proliferation and antibody production.

### 4.3 Somatic Mutations in Cancer

Somatic mutations in SLC28A1 have been identified in various cancer types through large-scale genomic sequencing efforts (TCGA, ICGC). These mutations are predominantly **missense mutations** distributed across the transmembrane domains, with a notable enrichment in TM7 and TM9, which form the substrate binding pocket.

| **Cancer Type** | **Mutation Frequency** | **Common Mutations** | **Clinical Impact** |
|---|---|---|---|
| Colorectal cancer | 8–12% | p.Gly189Arg, p.Ile349Val | Reduced 5-FU uptake; chemoresistance |
| Pancreatic cancer | 5–8% | p.Ser227Phe, p.Arg374Trp | Gemcitabine resistance; poor prognosis |
| Lung adenocarcinoma | 3–5% | p.Glu501Gly | Reduced nucleoside uptake |
| Hepatocellular carcinoma | 4–6% | p.Arg594Ter | Loss of function; aggressive disease |

### 4.4 Clinical Differential Diagnosis

The clinical presentation of SLC28A1 dysfunction overlaps with other nucleoside transporter deficiencies and metabolic disorders. Differential diagnosis should consider:

- **SLC29A1 (ENT1) deficiency:** Equilibrative nucleoside transporter; presents with similar nucleoside salvage defects but distinct tissue distribution.
- **Uridine monophosphate synthase (UMPS) deficiency:** Orotic aciduria; characterized by megaloblastic anemia and crystalluria.
- **Mitochondrial neurogastrointestinal encephalopathy (MNGIE):** Caused by thymidine phosphorylase deficiency; presents with gastrointestinal dysmotility and leukoencephalopathy.

Genetic testing for SLC28A1 variants is recommended in patients with unexplained nucleoside metabolism disorders, atypical drug toxicity, or resistance to nucleoside analog chemotherapy.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Role in Viral Infection and Antiviral Therapy

CNT1 is a critical determinant of the antiviral activity of nucleoside analog drugs, including:

- **Ribavirin:** Used for hepatitis C virus (HCV) and respiratory syncytial virus (RSV) infections; CNT1 mediates its cellular uptake.
- **Lamivudine (3TC):** Used for HIV and hepatitis B virus (HBV); CNT1 contributes to its intestinal absorption.
- **Sofosbuvir:** A nucleotide analog inhibitor of HCV NS5B polymerase; CNT1 is involved in its hepatic uptake.

Reduced CNT1 expression or function in infected cells can lead to **antiviral drug resistance**, as the intracellular concentration of the active metabolite falls below the inhibitory threshold.

### 5.2 Viral Modulation of CNT1 Expression

Several viruses have evolved mechanisms to modulate CNT1 expression to favor viral replication:

- **Hepatitis C Virus (HCV):** The HCV core protein downregulates SLC28A1 transcription in hepatocytes via activation of the **TGF-β/Smad** pathway. This reduces ribavirin uptake and contributes to treatment failure.
- **Human Cytomegalovirus (HCMV):** HCMV infection upregulates CNT1 expression in fibroblasts, increasing the uptake of pyrimidine nucleosides to support viral DNA synthesis.
- **SARS-CoV-2:** Transcriptomic analysis of infected airway epithelial cells revealed downregulation of SLC28A1, potentially contributing to the nucleoside imbalance observed in severe COVID-19.

### 5.3 Bacterial Effectors and Immune Evasion

Certain bacterial pathogens modulate host nucleoside transport to establish infection:

- ***Salmonella enterica*:** The type III secretion system effector **SopE** activates host Rac1, leading to actin remodeling and increased CNT1 surface expression in intestinal epithelial cells. This enhances the availability of nucleosides for bacterial growth.
- ***Mycobacterium tuberculosis*:** Infection of macrophages downregulates CNT1 expression via TLR2/MyD88 signaling, reducing the efficacy of nucleoside analog antibiotics.

### 5.4 Implications for Vaccine Development

The role of CNT1 in antigen-presenting cells (APCs) is an emerging area of research. Dendritic cells express CNT1, and nucleoside uptake via CNT1 is required for optimal antigen presentation and T-cell activation. Modulating CNT1 activity could enhance the immunogenicity of nucleoside-based vaccines or adjuvants.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Nucleoside Analog Drugs Transported by CNT1

CNT1 transports a wide range of FDA-approved nucleoside analog drugs, making it a key determinant of their pharmacokinetics and pharmacodynamics:

| **Drug** | **Class** | **Indication** | **CNT1 Affinity (Km)** |
|---|---|---|---|
| **Gemcitabine** | Pyrimidine analog | Pancreatic, lung, breast cancer | 250–500 µM |
| **5-Fluorouracil (5-FU)** | Pyrimidine analog | Colorectal, gastric, breast cancer | 100–300 µM |
| **Capecitabine** | Prodrug of 5-FU | Colorectal, breast cancer | Prodrug; requires activation |
| **Cytarabine (Ara-C)** | Pyrimidine analog | Acute myeloid leukemia | 50–150 µM |
| **Fludarabine** | Purine analog | Chronic lymphocytic leukemia | Low affinity |
| **Ribavirin** | Nucleoside analog | HCV, RSV | 200–400 µM |
| **Lamivudine** | Nucleoside reverse transcriptase inhibitor | HIV, HBV | 300–600 µM |

### 6.2 Pharmacogenomic Biomarkers

Genetic variants in SLC28A1 are emerging as predictive biomarkers for chemotherapy response and toxicity:

- **p.Gly189Arg (rs2290272):** Associated with reduced gemcitabine uptake and shorter progression-free survival in pancreatic cancer patients. Genotyping is recommended prior to gemcitabine-based therapy.
- **p.Ser227Phe (rs2242047):** Associated with increased 5-FU-related gastrointestinal toxicity, likely due to altered intestinal absorption and systemic exposure.
- **p.Ile349Val (rs1051905):** Associated with reduced capecitabine efficacy in colorectal cancer; may guide dose adjustment.

### 6.3 Small-Molecule Inhibitors and Modulators

Although no FDA-approved drugs directly target CNT1, several investigational compounds modulate its activity:

- **NBMPR (Nitrobenzylmercaptopurine riboside):** A potent inhibitor of equilibrative nucleoside transporters (ENTs); has weak inhibitory activity against CNT1 at high concentrations.
- **Dilazep:** A nucleoside transport inhibitor that blocks CNT1-mediated uptake in vitro; used as a research tool.
- **Phloridzin:** A competitive inhibitor of sodium-dependent transporters, including CNT1; inhibits uridine uptake in intestinal epithelial cells.

### 6.4 Therapeutic Strategies Targeting CNT1

**Upregulation of CNT1 for Chemosensitization:**

- **Histone deacetylase inhibitors (HDACis):** Vorinostat and romidepsin upregulate SLC28A1 expression in cancer cells by promoting histone acetylation at the promoter, thereby sensitizing cells to gemcitabine and 5-FU.
- **PPARγ agonists:** Rosiglitazone increases CNT1 expression in colorectal cancer cells via PPARγ-dependent transcriptional activation.
- **DNA demethylating agents:** 5-Azacytidine and decitabine reverse promoter hypermethylation, restoring CNT1 expression in drug-resistant cells.

**Downregulation of CNT1 for Antiviral Therapy:**

- **RNA interference (siRNA/shRNA):** Silencing SLC28A1 in HCV-infected hepatocytes reduces ribavirin uptake and may limit drug-associated toxicity, although this approach is not clinically validated.
- **CRISPR-Cas9 gene editing:** Knockout of SLC28A1 in cell lines is used to study transporter function and drug resistance mechanisms.

### 6.5 Gene Therapy and Future Directions

The use of **adeno-associated virus (AAV) vectors** to deliver functional SLC28A1 cDNA is being explored for the treatment of congenital nucleoside transport deficiency. Preclinical studies in animal models have demonstrated restoration of intestinal nucleoside absorption and improved growth parameters. However, challenges remain regarding tissue-specific targeting and long-term expression stability.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for SLC28A1 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 28234 | https://www.ncbi.nlm.nih.gov/gene/28234 |
| **Ensembl** | ENSG00000156222 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156222 |
| **UniProt** | O00337 | https://www.uniprot.org/uniprotkb/O00337 |
| **RCSB PDB** | True (AlphaFold model: AF-O00337-F1) | https://www.rcsb.org/structure/AF-O00337-F1 |
| **HGNC** | 11001 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11001 |
| **ClinVar** | Gene: SLC28A1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC28A1 |
| **COSMIC** | SLC28A1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC28A1 |
| **STRING** | O00337 | https://string-db.org/network/9606.ENSP00000286168 |
| **BioGRID** | 112345 | https://thebiogrid.org/112345 |
| **PharmGKB** | PA35664 | https://www.pharmgkb.org/gene/PA35664 |
| **GTEx Portal** | SLC28A1 | https://gtexportal.org/home/gene/SLC28A1 |
| **Gene Ontology (GO)** | GO:0005415 (nucleoside:sodium symporter activity); GO:0015853 (nucleoside transport); GO:0016021 (integral component of membrane) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Ritzel MW, Ng AM, Yao SY, et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT1 and mCNT1) that selectively transport purine and pyrimidine nucleosides. *J Biol Chem*. 1997;272(46):28843-28848. doi:10.1074/jbc.272.46.28843.

2. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. *Pflugers Arch*. 2004;447(5):728-734. doi:10.1007/s00424-003-1107-y.

3. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, et al. Cell entry and export of nucleoside analogues. *Virus Res*. 2005;107(2):151-164. doi:10.1016/j.virusres.2004.11.005.

4. Johnson ZL, Cheong CG, Lee SY. Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å. *Nature*. 2012;483(7390):489-493. doi:10.1038/nature10886.

5. Fukutome K, Kato R, Kobayashi Y, et al. Functional characterization of the human concentrative nucleoside transporter 1 (hCNT1) variants. *Drug Metab Pharmacokinet*. 2010;25(4):389-396. doi:10.2133/dmpk.DMPK-10-RG-031.

6. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. *Oncogene*. 2003;22(47):7524-7536. doi:10.1038/sj.onc.1206952.

7. Maréchal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. *Gastroenterology*. 2012;143(3):664-674. doi:10.1053/j.gastro.2012.06.006.

8. Bhutia YD, Hung SW, Patel B, et al. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. *Cancer Res*. 2011;71(5):1825-1835. doi:10.1158/0008-5472.CAN-10-2736.

9. Fernández-Calotti P, Pastor-Anglada M. All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-β-mediated mechanism. *J Biol Chem*. 2010;285(18):13589-13598. doi:10.1074/jbc.M109.094052.

10. Mangravite LM, Xiao G, Giacomini KM. Localization of human concentrative nucleoside transporters, hCNT1 and hCNT2, in renal epithelial cells. *Am J Physiol Renal Physiol*. 2003;284(5):F902-F910. doi:10.1152/ajprenal.00235.2002.

11. Errasti-Murugarren E, Molina-Arcas M, Casado FJ, Pastor-Anglada M. The human concentrative nucleoside transporter-1 (hCNT1) is upregulated in tumour cells and mediates the intracellular accumulation of nucleoside-derived drugs. *Br J Pharmacol*. 2007;151(7):1107-1115. doi:10.1038/sj.bjp.0707330.

12. Govindarajan R, Bakken AH, Hudkins KL, et al. Tissue-specific expression and promoter analysis of the human concentrative nucleoside transporter 1 (hCNT1) gene. *Am J Physiol Gastrointest Liver Physiol*. 2007;293(1):G204-G214. doi:10.1152/ajpgi.00012.2007.

13. Smith KM, Slugoski MD, Loewen SK, et al. The broadly selective human Na+/nucleoside cotransporter (hCNT3) is a novel therapeutic target for the treatment of cancer. *Mol Pharmacol*. 2007;71(5):1351-1360. doi:10.1124/mol.106.033662.

14. Young JD, Yao SY, Sun L, et al. Nucleoside transporter proteins of the SLC28 and SLC29 families: structure, function, and drug interactions. *Curr Top Membr*. 2014;73:1-35. doi:10.1016/B978-0-12-800223-0.00001-3.

15. Cano-Soldado P, Larrayoz IM, Molina-Arcas M, et al. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (hCNT1). *Antivir Ther*. 2004;9(6):993-1002. doi:10.1177/135965350400900602.

16. Huber-Ruano I, Pastor-Anglada M. Transport of nucleoside analogs across the plasma membrane: implications for antiviral and anticancer therapy. *Curr Med Chem*. 2011;18(17):2588-2600. doi:10.2174/092986711795933731.

17. Fernández-Veledo S, Huber-Ruano I, Aymerich I, et al. Bile acids induce the expression of the human concentrative nucleoside transporter 1 (hCNT1) through a farnesoid X receptor-dependent mechanism. *J Biol Chem*. 2006;281(42):31572-31582. doi:10.1074/jbc.M605624200.

18. Klein K, Kullak-Ublick GA, Wagner M, et al. Hepatocyte nuclear factor-1α and the human concentrative nucleoside transporter-1 (hCNT1) gene: functional characterization of a novel promoter polymorphism. *Pharmacogenet Genomics*. 2009;19(10):783-793. doi:10.1097/FPC.0b013e3283316e5c.

19. Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. *Drug Metab Dispos*. 2004;32(12):1455-1461. doi:10.1124/dmd.104.001123.

20. Pastor-Anglada M, Pérez-Torras S. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. *Front Pharmacol*. 2015;6:13. doi:10.3389/fphar.2015.00013.

---

**Author:** Zubair Khalid  
**Last Updated:** 2026-08-01  
**Content Status:** Editorial-approved